Krystal Biotech, Inc. Common Stock (KRYS) Stock Price

KRYSStock

$356.19+127.08%52W

Market Cap$10.54B

P/E47.42x

PEG Ratio—

Div yield—

Beta0.48

KRYS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)9.38%

Price vs S&P 500 (4W)-9.23%

VGM Score56.36

P/E Ratio (Annual)47.42x

P/CF (Annual)48.36x

Book Value / Share (Quarterly)$45.92

P/TBV (Annual)5.56x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$8.71

Price vs S&P 500 (YTD)26.65%

Gross Margin (TTM)94.64%

Net Profit Margin (TTM)54.82%

EPS (TTM)$7.98

10-Day Avg Trading Volume0.20M

EPS Excl Extra (TTM)$7.98

EPS (Annual)$6.84

ROI (Annual)16.80%

Gross Margin (Annual)94.08%

Cash / Share (Quarterly)$28.57

P/E Basic Excl Extra (TTM)40.23x

Revenue Growth QoQ (YoY)24.14%

P/E Normalized (Annual)47.42x

ROA (Last FY)15.36%

Revenue Growth TTM (YoY)22.63%

EBITD / Share (TTM)$6.71

ROE (5Y Avg)-2.18%

Operating Margin (TTM)44.89%

Cash Flow / Share (Annual)$6.47

P/B Ratio7.15x

P/B Ratio (Quarterly)8.06x

Net Income / Employee (Annual)$694,300

EV / Revenue (TTM)21.08x

Net Interest Coverage (TTM)-52.52x

ROA (TTM)17.65%

EPS Growth QoQ (YoY)38.65%

EV / EBITDA (TTM)45.61x

EPS Incl Extra (Annual)$6.84

Current Ratio (Annual)9.95x

Quick Ratio (Quarterly)7.73x

3-Month Avg Trading Volume0.38M

52-Week Price Return127.08%

EV / Free Cash Flow (Annual)49.15x

P/E Incl Extra (TTM)40.23x

Revenue / Employee (TTM)$1,493,200

Tangible BV / Share (Quarterly)$26.81

P/S Ratio (Annual)24.96x

Asset Turnover (Annual)0.29x

52-Week High$382.54

EPS Excl Extra (Annual)$6.84

CapEx CAGR (5Y)-4.24%

Tangible BV CAGR (5Y)60.21%

26-Week Price Return20.63%

Quick Ratio (Annual)9.28x

13-Week Price Return12.32%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.32x

Enterprise Value$9.29B

Asset Turnover (TTM)0.32x

Book Value / Share Growth (5Y)23.03%

Revenue / Employee (Annual)$1,319,100

Pretax Margin (Annual)48.69%

Cash / Share (Annual)$28.36

3-Month Return Std Dev42.58%

Net Income / Employee (TTM)$818,500

ROE (Last FY)16.80%

Net Interest Coverage (Annual)-9.83x

EPS Basic Excl Extra (Annual)$6.84

P/FCF (TTM)37.68x

Receivables Turnover (TTM)3.52x

EV / Free Cash Flow (TTM)36.02x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$7.98

ROI (TTM)19.34%

P/S Ratio (TTM)22.05x

Revenue / Share (Annual)$12.99

Tangible BV / Share (Annual)$20.27

Forward P/E42.52x

Price vs S&P 500 (52W)108.77%

P/E Ratio (TTM)40.23x

EPS Growth TTM (YoY)62.37%

Year-to-Date Return38.61%

5-Day Price Return2.67%

EPS Normalized (Annual)$6.84

ROA (5Y Avg)-2.21%

Net Profit Margin (Annual)52.64%

Month-to-Date Return0.18%

Cash Flow / Share (TTM)$-0.95

EBITD / Share (Annual)$5.58

Operating Margin (Annual)41.45%

LT Debt / Equity (Annual)0.00x

P/CF (TTM)35.67x

ROI (5Y Avg)-2.18%

P/E Excl Extra (TTM)40.23x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$7.98

P/TBV (Quarterly)3.84x

P/B Ratio (Annual)5.86x

Inventory Turnover (TTM)0.62x

Pretax Margin (TTM)51.45%

Book Value / Share (Annual)$41.78

Price vs S&P 500 (13W)9.53%

Beta0.48x

P/FCF (Annual)51.42x

Revenue / Share (TTM)$14.37

ROE (TTM)19.34%

52-Week Low$136.73

vGradeD

gGradeB

mGradeB

vgmGradeC

KRYS Earnings Surprise History

Q2 251.29est. 1.44

Q3 252.66est. 1.12

Q4 251.70est. 1.61

Q1 261.83est. 1.42

Q2 261.79est. 1.91

KRYS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.28

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Krystal Biotech, Inc. Common Stock

Krystal Biotech is a commercial-stage biotechnology company developing genetic medicines for diseases with high unmet medical needs using its proprietary HSV-1-based gene therapy platform. The company commercializes VYJUVEK, its lead therapeutic product, across the United States, European Union, and Japan. Krystal Biotech leverages its platform to create vectors that deliver therapeutic genes to target cells with exclusive rights to develop, manufacture, and commercialize VYJUVEK globally.